← Back to Search

Checkpoint Inhibitor

Nivolumab + Relatlimab for Melanoma (RELATIVITY-098 Trial)

Phase 3
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adolescent participants between 12 and < 18 years of age must have a Lansky/Karnofsky performance score ≥ 80%
Tumor tissue must be provided for biomarker analyses
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 90 months
Awards & highlights

RELATIVITY-098 Trial Summary

This trial will compare nivolumab + relatlimab to nivolumab alone to see if the combo is more effective in treating melanoma.

Who is the study for?
Adults and adolescents with completely removed stage III-IV melanoma can join this trial. They must be in good physical condition, not have had prior immunotherapy, or any serious medical issues. People with eye melanoma, brain metastases, recent COVID-19 infection, heart inflammation history, or autoimmune diseases cannot participate.Check my eligibility
What is being tested?
The study is testing the effectiveness of combining two drugs (Nivolumab + Relatlimab) versus using Nivolumab alone as a follow-up treatment to prevent melanoma from coming back after surgery.See study design
What are the potential side effects?
Possible side effects include immune-related reactions affecting various organs like the liver or lungs, skin rash, hormone gland problems (like thyroid), infusion reactions during drug administration and fatigue.

RELATIVITY-098 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a teenager and can do most activities without help.
Select...
I can provide a sample of my tumor for testing.
Select...
I am 18 or older and can do all my own self-care.
Select...
I've been confirmed disease-free by a recent physical exam and imaging.
Select...
I was diagnosed with Stage IIIA/B/C/D or IV melanoma and had surgery to remove it completely.

RELATIVITY-098 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 90 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 90 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recurrence-Free Survival (RFS) time per Investigator assessment
Secondary outcome measures
Distant Metastasis-Free Survival (DMFS) time per Investigator assessment
Incidence of AEs leading to discontinuation (DC)
Incidence of Adverse Events (AEs)
+13 more

RELATIVITY-098 Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm B: NivolumabExperimental Treatment1 Intervention
Monotherapy
Group II: Arm A: Nivolumab Plus RelatlimabExperimental Treatment1 Intervention
Combination
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
2014
Completed Phase 3
~4750

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,650 Previous Clinical Trials
4,129,782 Total Patients Enrolled
177 Trials studying Melanoma
56,344 Patients Enrolled for Melanoma

Media Library

Nivolumab (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05002569 — Phase 3
Melanoma Research Study Groups: Arm A: Nivolumab Plus Relatlimab, Arm B: Nivolumab
Melanoma Clinical Trial 2023: Nivolumab Highlights & Side Effects. Trial Name: NCT05002569 — Phase 3
Nivolumab (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05002569 — Phase 3
~412 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top